Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression

COMPASS Pathways Plc (CMPS) — LONDON & JERSEY CITY, N.J., November 09, 2026--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the Company completed its submission of a New Drug Application (NDA) to the U.S. FDA for COMP360 psilocybin, its investigational synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD).

Source: Business Wire — read the full announcement there.

See our COMPASS Pathways company profile for background, links, and more COMPASS Pathways news.